[HTML][HTML] PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with …
…, L Mulder, G Bogina, J Sanders, YH Liu… - Breast Cancer …, 2023 - Springer
Background Invasive breast cancer patients are increasingly being treated with neoadjuvant
chemotherapy; however, only a fraction of the patients respond to it completely. To prevent …
chemotherapy; however, only a fraction of the patients respond to it completely. To prevent …
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study
…, K Clements, Y Ren, C Cresta, J Timbres, YH Liu… - bmj, 2023 - bmj.com
Objective To examine the association between size and margin status of ductal carcinoma
in situ (DCIS) and risk of developing ipsilateral invasive breast cancer and ipsilateral DCIS …
in situ (DCIS) and risk of developing ipsilateral invasive breast cancer and ipsilateral DCIS …
Predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies
…, HM Horlings, L Mulder, G Bogina, J Sanders, YH Liu… - medRxiv, 2022 - medrxiv.org
Purpose Invasive breast cancer patients are increasingly being treated with neoadjuvant
chemotherapy, however, only a fraction of the patients respond to it completely. To prevent over-…
chemotherapy, however, only a fraction of the patients respond to it completely. To prevent over-…
Abstract P1-22-02: Subsequent risk of ipsilateral breast events in a multinational DCIS cohort of 48.619 patients: A meta-analysis within the PRECISION consortium
…, SW van den Belt-Dusebout, C Cresta, YH Liu… - Cancer Research, 2022 - AACR
… Yat-Hee Liu … Renée SJM Schmitz, Sandra W van den Belt-Dusebout, Chiara Cresta,
Yat-Hee Liu, Michael Schaapveld, Karen Clements, Jasmine Timbres, Danalyn T Byng, Marc D …
Yat-Hee Liu, Michael Schaapveld, Karen Clements, Jasmine Timbres, Danalyn T Byng, Marc D …
Deep Learning for Predicting Invasive Recurrence of Ductal Carcinoma in Situ: Leveraging Histopathology Images and Clinical Features
S Doyle, EH Lips, E Marcus, L Mulder, YH Liu… - papers.ssrn.com
Background: Ductal Carcinoma In Situ (DCIS) can progress to ipsilateral invasive breast
cancer (IBC) but over 75% of DCIS lesions do not progress if untreated. Currently, DCIS that …
cancer (IBC) but over 75% of DCIS lesions do not progress if untreated. Currently, DCIS that …
Subsequent invasive breast cancer risk after DCIS treatment in multinational PRECISION consortium cohorts comprising 48,576 patients
…, K Clements, Y Ren, C Cresta, J Timbres, YH Liu… - Cancer Research, 2022 - AACR
Background: Although DCIS is a precursor of invasive breast cancer (IBC), most DCIS lesions
never will progress. As we cannot distinguish reliably progressive from harmless DCIS yet, …
never will progress. As we cannot distinguish reliably progressive from harmless DCIS yet, …
Association of DCIS size and margin status with the risk of developing breast cancer post-treatment in a multinational pooled cohort of 47,695 women
A van den Belt-Dusebout - 2023 - bmj.com
Confidential: For Review Only Page 1 Confidential: For Review Only Association of DCIS
size and margin status with the risk of developing breast cancer post-treatment in a …
size and margin status with the risk of developing breast cancer post-treatment in a …
[BOOK][B] Somerset: Editorial apparatus
JD Stokes, RJ Alexander - 1996 - books.google.com
… Quo die comparuit et iuratus fassus est yat hee was absent from the churche on the said
sonday, but did not daunce vntill after evening prayer was ended, verte folium ad + I + but …
sonday, but did not daunce vntill after evening prayer was ended, verte folium ad + I + but …
[CITATION][C] Subsequent risk of ipsilateral breast events in a multinational DCIS cohort of 48.619 patients: A meta-analysis within the PRECISION consortium
…, C Cresta, YH Liu… - CANCER …, 2022 - AMER ASSOC CANCER …
